• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Stealth BioTherapeutics Corp. ADS

    11/28/22 4:30:29 PM ET
    $MITO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MITO alert in real time by email
    15-12G 1 d427006d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Commission File Number: 001-38810

     

     

    STEALTH BIOTHERAPEUTICS CORP

    (Exact name of registrant as specified in its charter)

     

     

    Stealth BioTherapeutics Corp

    c/o Intertrust Corporate Services (Cayman) Limited

    One Nexus Way, Camana Bay

    Grand Cayman

    KY1-9005 Cayman Islands

    Telephone: (617) 600-6888

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Ordinary Shares, par value US$0.0003 per share

    American Depositary Shares, each representing 12 ordinary shares

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      ☒

    Rule 12g-4(a)(2)

      ☐

    Rule 12h-3(b)(1)(i)

      ☒

    Rule 12h-3(b)(1)(ii)

      ☐

    Rule 15d-6

      ☐

    Rule 15d-22(b)

      ☐

    Approximate number of holders of record as of the certification or notice date: five

     

     

     


    Pursuant to the requirements of the Securities Exchange Act of 1934, Stealth BioTherapeutics Corp has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

        Stealth BioTherapeutics Corp
    Date: November 28, 2022    
        By:  

    /s/ Irene P. McCarthy

        Name:   Irene P. McCarthy
        Title:   Chief Executive Officer
    Get the next $MITO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MITO

    DatePrice TargetRatingAnalyst
    7/1/2021$3.00Buy
    Maxim Group
    More analyst ratings

    $MITO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stealth BioTherapeutics Corp Announces Completion of Merger

      BOSTON, Nov. 16, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO) (the "Company" or "Stealth BioTherapeutics"), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the completion of the merger (the "Merger") with Stealth Merger Sub Limited, an exempted company with limited liability incorporated under the law of the Cayman Islands ("Merger Sub"), pursuant to the previously announced Agreement and Plan of Merger, dated as of July 31, 2022 (the "Merger Agreement"), among the Company, Stealth Parent Limited, an exempted company with limited liabilit

      11/16/22 4:01:00 PM ET
      $MITO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stealth BioTherapeutics Announces SBT-272 Data Updates and Orphan Drug Designation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

      SBT-272 Phase 1 safety and tolerability data support further clinical development SBT-272 was neuroprotective and reduced neuroinflammation in ALS preclinical model SBT-272 Granted Orphan Drug Designation for Treatment of ALS BOSTON, Nov. 1, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced encouraging Phase 1 data on the safety and tolerability of SBT-272, a next-generation small molecule designed to reach therapeutic concentrations in the brain and to restore mitochondrial structure and functi

      11/1/22 7:30:00 AM ET
      $MITO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stealth BioTherapeutics Corp to Hold Extraordinary General Meeting of Shareholders

      BOSTON, Oct. 7, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that it has called an extraordinary general meeting of shareholders (the  "EGM"), to be held at 9:30 a.m. (New York City time) on November 15, 2022, at Foley & Lardner LLP, 111 Huntington Ave Suite 2600, Boston, MA 02199, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of July 31, 2022 (the "Merger Agreem

      10/7/22 4:01:00 PM ET
      $MITO
      Biotechnology: Pharmaceutical Preparations
      Health Care